Drugs Made In America Acquisition (DMAAR) Payables (2024 - 2025)

Drugs Made In America Acquisition (DMAAR) posted Payables of $222184.0 for Q4 2025, up 22118.4% on a QoQ basis from $1000.0 in Q2 2025, and down 69.96% year-over-year from $739604.0 in Q4 2024.

Drugs Made In America Acquisition (DMAAR) Payables (2024 - 2025) Analysis & Trends

Drugs Made In America Acquisition's Payables history runs 2 years deep, the most recent figure standing at $222184.0 for Q4 2025.

  • Quarterly Payables fell 69.96% year-over-year to $222184.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $222184.0 (down 69.96% YoY) and the FY2025 annual result came in at $222184.0, down 69.96% from the prior year.
  • Payables was $222184.0 for Q4 2025 at Drugs Made In America Acquisition, up from $1000.0 in the prior quarter.
  • Across five years, Payables topped out at $739604.0 in Q4 2024 and bottomed at $1000.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Payables (Qtr)
1 SIM Acquisition Corp. I 314.52 Mn 314.52 Mn - 768,221.00
2 Thayer Ventures Acquisition 208.29 Mn 208.29 Mn - 26,110.00
3 Newbury Street II Acquisition 185.26 Mn 185.26 Mn - 102,122.00
4 Dynamix 178.78 Mn 178.78 Mn - 3.69 Mn
5 Hallmark Venture 103.01 Mn 102.76 Mn - 24,630.00
6 Voyager Acquisition 99.58 Mn 99.45 Mn - 1.06 Mn
7 Gores Holdings X 95.80 Mn 95.37 Mn - -1.52 Mn
8 Archimedes Tech SPAC Partners 89.88 Mn 89.88 Mn - 1,239.00
9 Cohen Circle Acquisition 80.05 Mn 80.05 Mn - -
10 Drugs Made In America Acquisition 1.46 Mn 1.46 Mn - 222,184.00

Historic Data

Download Data
DateValue
Dec 31, 2025 222,184.00
Jun 30, 2025 1,000.00
Mar 31, 2025 60,898.00
Dec 31, 2024 739,604.00